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Background: One of the most common complications in infants under parenteral 
nutrition treatment is parenteral nutrition-associated cholestasis (PNAC). The etiol-
ogy of PNAC is thought to be multifactorial. The aims of this study were to evaluate 
the risk factors for PNAC in our neonatal intensive care unit and determine useful 
predictors.
Methods: This study enrolled premature infants (gestational age < 36 weeks) who were 
admitted to our neonatal intensive care unit and treated with parenteral nutrition 
infusion for at least 2 weeks between January 2004 and January 2007. Multiple pos-
sible risk factors were analyzed by a retrospective review study design. PNAC was 
defined as direct bilirubin greater than 1.5 mg/dL during parenteral nutrition.
Results: A total of 62 premature infants with prolonged course of parenteral nutrition 
were eligible for this study; 11 (17.74%) of the infants developed PNAC. There were 
significant differences in terms of gestational age, birth body weight, duration of 
parenteral nutrition, septic episodes, and average energy intake during the 2nd and 
3rd weeks of life between infants with cholestasis and those without cholestasis. Of 
these risk factors, the duration of parenteral nutrition was most significant after 
multivariate logistic regression analysis.
Conclusion: Young gestational age, low birth body weight, more sepsis episodes, and 
long duration of parenteral nutrition were significant risk factors for PNAC in our study. 
Low energy intake during the 2nd and 3rd weeks of life is a predictor for PNAC.
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1.  Introduction
Parenteral nutrition has been used for years in our 
neonatal intensive care unit (NICU). However, pro-
longed infusion of parenteral nutrition may induce 
many complications, which affect the hepatobil-
iary system. One of the most common complica-
tions in infants is parenteral nutrition-associated 
cholestasis (PNAC).1 Previous studies have shown 
that the etiology of PNAC is multifactorial. Risk 
factors for the development of PNAC include pre-
maturity, lack of enteral feeding, prolonged dura-
tion of parenteral nutrition infusion and sepsis.2 
However, there are very few studies of PNAC in in-
fants in Taiwan.3,4 The early prediction and recog-
nition of PNAC in the preterm infants may prevent 
unnecessary expenditure and prevent possible in-
jury by further parenteral nutrition. The aims of this 
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study were to evaluate the risk factors for PNAC in 
our NICU and to identify new clinically useful pre-
dictors for PNAC.
2.  Materials and Methods
2.1.  Patients and enrollment criteria
All of the neonates who were admitted to Kaohsiung 
Medical University Hospital between January 1, 2004 
and January 31, 2007 were considered for this anal-
ysis if they fulfilled the following criteria: (1) ges-
tational age < 36 weeks, (2) admission before 2 days 
of age, and (3) the infant then received parenteral 
nutrition infusion for at least 14 days. Infants with 
other causes of cholestasis or other severe congen-
ital anomalies were excluded from this study. The 
studied patients were followed up until discharge, 
cessation of parenteral nutrition supply or until 
death. This was a retrospective review study. PNAC 
was defined as the presence of direct biliru-
bin > 1.5 mg/dL during parenteral nutrition.
2.2.  Parenteral nutrition protocol
The nutritional protocol during the study period 
was standardized. The components of parenteral 
nutrition were adjusted and individualized accord-
ing to the clinical conditions. Amino acids were sup-
plied with Aminosteril infant® 10% (Fresenius Kabi 
AG, Hafnerstraße, Graz, Austria), and the dosage 
did not exceed 3 mg/kg/day. Lipids were supplied 
with Lipofundin® MCT/LCT 20% (B. Braun Melsungeu 
AG, Melsungen, Germany) after neonatal hyperbil-
irubinemia showed improvement, and the dose did 
not exceed 3 mg/kg/day. Dextrose infusion was 
started after birth with low glucose infusion rate, 
which was between 6 and 8 mg/kg/minutes and 
adjusted according to blood sugar level and clinical 
conditions. The glucose infusion rate did not exceed 
14 mg/kg/minute. Trace minerals were supplied daily 
with Trace Element® (China Chemical & Pharmaceu-
tical Co., Ltd., Hsinchu County, Taiwan) according 
to the infants body weight.
2.3.  Risk factors and definitions
Possible risk factors were recorded including ges-
tational age, birth body weight, small for gesta-
tional age (SGA), duration of parenteral nutrition 
infusion, Apgar score, episodes of culture-confirmed 
sepsis, operations performed and number of opera-
tions, age at initial feeding, age at which lipid infu-
sion was started, duration of lipid infusion, presence 
of symptomatic patent ductus arteriosus necessi-
tating an operation, bronchopulmonary dysplasia, 
necrotizing enterocolitis and average energy intake 
during the 1st, 2nd and 3rd weeks of life.
SGA was defined as birth body weight below the 
10th percentile for gestational age on a fetal growth 
chart.5 Septic episodes were defined as positive 
blood cultures in association with one or more symp-
toms of systemic inflammatory response syndrome 
such as fever, low peripheral skin temperature, hy-
potonia, hypotension and unstable vital signs. The 
age at initial feeding was defined as the age of start-
ing enteral feeding with formula or breast milk. We 
also calculated daily energy intake as the sum of 
enteral and parenteral nutrition during each week 
and divided by 7 days.
2.4.  Statistical analysis
Differences in possible risk factors between cholesta-
sis and non-cholestasis infants were compared by 
non-parametric tests for continuous data and 
Fisher’s exact tests for categorical data. Because of 
differences in gestational age and birth body 
weight between the two groups, the comparisons of 
the measurements between two groups were fur-
ther evaluated by analysis of covariance (ANCOVA) 
models with covariates including gestational age 
and birth body weight. A p-value < 0.05 was consid-
ered statistically significant. To eliminate interac-
tions between these factors, multivariate logistic 
regression analysis was used to identify the most 
significant risk factors. Receiver operating charac-
teristic (ROC) curve analysis was then used to de-
termine the optimal cut-off points for statistically 
significant risk factors to predict PNAC. The area 
under the ROC curve for different risk factors was 
also calculated. JMP software 6.0 (SAS Inc., Cary, 
NC, USA) was used for all statistical analyses.
3.  Results
During the study period, 983 infants were admitted 
to our NICU. Only 62 infants fulfilled our criteria 
and were included in this study. Among these 62 
infants, 11 infants (17.74%, 95% confidence inter-
val: 10.20−29.04%) developed cholestasis. The 
maximum bilirubin level of these 11 infants ranged 
1.95−18.56 mg/dL (mean ± standard deviation, 6.45 ±
5.99 mg/dL). These infants developed cholestasis at 
the mean age of 57.50 ± 25.80 (range: 18−87) days. 
Three infants died due to sepsis and respiratory fail-
ure, and all three had cholestasis. Among of eight 
surviving infants with cholestasis, the cholestasis 
persisted for 36.80 ± 23.02 (2−61) days.
Table 1 shows the demographic data and the po-
tential risk factors in premature infants with and 
without PNAC. The infants with cholestasis had 
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significantly lower gestational age and lower birth 
body weight. The proportion of sex and SGA did not 
differ significantly between the cholestasis and 
non-cholestasis infants. Longer parenteral nutrition 
duration, lower Apgar score at 5 minutes old, more 
septic episodes, delay of initial feeding, undergoing 
more operations, longer lipid infusion duration and 
lower energy intake during 2nd and 3rd weeks of 
life seemed to show significant risk for developing 
cholestasis in these patients. To eliminate a poten-
tial influence of covariates such as gestational age 
and birth body weight, we used an ANCOVA model 
to adjust the statistical results. After adjustment, 
only the duration of parenteral nutrition, number 
of septic episodes and average energy intake during 
the 2nd and 3rd weeks of life were significantly as-
sociated with the development of PNAC.
Logistic regression analysis was then performed 
to evaluate the statistically significant variables 
presented in Table 1 as risk factors. Before perform-
ing the logistic regression, we combined two vari-
ables, namely energy intake in the 2nd week and 
energy intake in the 3rd week, into a variable for 
average energy intake between the 2nd and 3rd weeks 
because of the similarity and high correlation be-
tween these two variables. We entered these five 
statistically significant variables (gestational age, 
birth body weight, duration of parenteral nutrition, 
septic episodes, and average energy intake between 
the 2nd and 3rd weeks of life) into a multivariate 
logistic regression model. After controlling for these 
variables, the only risk factor associated with PNAC 
was the duration of parenteral nutrition (p = 0.0394, 
Table 2). An increase in duration of parenteral nu-
trition by 7 days, increased the risk for development 
of PNAC by 1.418-fold (95% confidence interval 
1.076−2.192) compared with patients without 
PNAC.
To clarify the role of these variables in predict-
ing the development of PNAC, ROC curve analysis 
of these factors was performed to determine the 
best cut-off values to predict the disease. The 
areas under the ROC curves were calculated to 
evaluate the quality of these variables as predic-
tors (Table 3). Parenteral nutrition for more than 
the cut-off point of 61 days had a higher sensitivity 
(0.91) and specificity (0.86) than any of the other 
variables evaluated.
Table 1  Characteristics and potential risk factors in premature infants with and without parenteral nutrition-
associated cholestasis
   Comparison between 
   cholestasis and non-
   cholestasis groups
 
Cholestasis
 
Non-cholestasis
 p value* p value from
 
group (n = 11)
  
group (n = 51)
  ANCOVA afte
    adjusting for 
    GA and BBW
Sex (male/total %) 72.73% (n = 8) 68.62% (n = 35) > 0.9999 0.5237
Gestational age (wks) 26.95 ± 1.62 30.19 ± 2.63 0.0002 —
Birth body weight (g) 948.18 ± 202.38 1434.71 ± 469.97 0.0014 —
Small for gestational age 9.09% (n = 1) 17.65% (n = 9) 0.6743 0.9996
Parenteral nutrition duration (d) 90.36 ± 34.49 41.43 ± 21.92 < 0.0001  < 0.0001
1-minute Apgar score 5.00 ± 1.41 5.82 ± 1.71 0.1443 0.7335
5-minute Apgar score 6.64 ± 0.92 7.86 ± 1.14 0.0016 0.1379
Episodes of sepsis 1.18 ± 1.08 0.41 ± 0.70 0.0040 0.0463
Number of operations received 0.82 ± 0.75 0.29 ± 0.61 0.0159 0.2393
Initial feeding (days old) 9.91 ± 8.55 4.82 ± 3.81 0.0029 0.0657
Lipofundin started date (days old) 8.00 ± 3.19 8.51 ± 3.10 0.6252 0.8402
Lipofundin duration (d) 53.43 ± 26.60 24.37 ± 20.38 0.0028 0.7304
Amino acid started date (days old) 3.27 ± 0.79 3.12 ± 1.24 0.6939 0.9950
Bronchopulmonary dysplasia 50.00% (n = 4) 21.57% (n = 11) 0.1837 0.4566
Patent ductus arteriosus needing operation 37.50% (n = 3) 13.73% (n = 7) 0.1255 0.2024
Necrotizing enterocolitis 0.00% (n = 0) 5.88% (n = 3) > 0.9999 0.3979
Average energy intake (kcal/kg/day)    
Week 1  40.13 ± 6.26 44.37 ± 8.22 0.1465 0.1914
Week 2 58.24 ± 13.16 74.88 ± 16.38 0.0025 0.0351
Week 3 75.30 ± 16.88 92.21 ± 16.65 0.0052 0.0105
*Continuous data were tested by non-parametric tests; categorical data were analyzed by Fisher’s exact test; ANCOVA = analysis 
of covariance; BBW = birth body weight; GA = gestational age.
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4.  Discussion
In this study, we evaluated risk factors and predic-
tors for the development of PNAC. We found that 
the duration of parenteral nutrition was the most 
significant risk factor and predictor for the devel-
opment of PNAC.
The rate of PNAC in previous studies ranged 
widely from 7.4% to 84% (17.74% in our study). The 
differences in rate of PNAC may be due to differ-
ences in patients in each study.6 At our NICU, 
cholestasis was diagnosed at 58.43 ± 24.30 (19−87) 
days of age, which is similar to the results of other 
studies (42 days or 1−4 weeks).7,8
Clinical experience has clearly established that 
the smallest premature infants are the most suscep-
tible to PNAC.9 Previous studies have also shown that 
the younger the gestational age, the higher the bil-
irubin concentrations.7,10 These results may be due 
to the physiological immaturity of the neonatal liver, 
leading to impaired hepatic transportation and 
metabolism of bile acids in prematurity.11,12 In our 
study, we also found prematurity and low birth body 
weight were significantly different between the 
premature infants with and without PNAC.
The duration of parenteral nutrition was the 
most significant risk factor and predictor for the 
development of PNAC according to the multivari-
ate logistic regression model. Although the associ-
ation between liver dysfunction and cholestasis 
with prolonged parenteral nutrition administration is 
well known by clinicians, the pathogenesis of PNAC 
is still poorly understood.9,13 PNAC may contribute 
to the direct correlation between the duration of 
parenteral nutrition and liver toxicity.2 Liver toxicity 
may result from consequences of the lack of physi-
ological enteral intake, the toxicity of parenteral 
nutrition components, and causes related to the 
underlying disease necessitating total parenteral 
nutrition.14
Infants with prolonged parenteral nutrition ex-
perience problems associated with enteral feeding 
for a certain period of time. It is well known that 
starting enteral feeding earlier can preserve intes-
tinal integrity, maintain intestinal hormone and 
enzyme secretion, and prevent bacterial translo-
cation.15 Early enteral feeding also delays the onset 
of liver dysfunction and leads to the resolution of 
jaundice, and might decrease the need and dura-
tion of parenteral nutrition.2 In our study, early 
enteral feeding exerted a protective effect against 
the development of cholestasis (p = 0.0029) before 
adjustment for gestational age and birth body 
weight. However, low total energy intake during 2nd 
Table 2 Multivariate logistic regression analysis for the prediction of parenteral nutrition-associated cholestasis
    
p-value for multivariate
Variables
 
Odds ratio
 
95% CI
 
 logistic analysis
  
Lower Upper
Gestational age (wks) 1.074 0.390 3.151 0.8890
Birth body weight (100 g) 0.797 0.309 1.529 0.5929
Duration of parenteral nutrition (wks) 1.418 1.076 2.192 0.0394
Episodes of sepsis (n) 1.037 0.260 3.644 0.9549
Average energy intake between the 0.470 0.164 1.038 0.0871
 2nd and 3rd weeks of life 
 (10 kcal/kg/day)
CI = confidence interval.
Table 3  Cut-off points, sensitivity, specificity and area under the curve for risk factors and predictors for
parenteral nutrition-associated cholestasis
Variables Cut-off point Sensitivity Specificity AUC*
Gestational age < 27 weeks and 5 days 0.8182 0.8431 0.85651
Birth body weight < 1040 g 0.8182 0.7843 0.86275
Duration of parenteral nutrition  > 61 d 0.9091 0.8627 0.86275
Episodes of sepsis > 1 episode 0.7273 0.6863 0.72549
Average energy intake between < 75.21 kcal/kg/day 0.8000 0.7660 0.79149
 the 2nd and 3rd weeks of life
*AUC = 0.5: prediction of cholestasis no better than chance; AUC = 1.0: perfect prediction; AUC = area under the curve.
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and 3rd weeks of life was related to the development 
of PNAC in our study. Low energy intake during the 
2nd and 3rd weeks of life may not be an independent 
risk factor of PNAC, but it might reflect the sever-
ity of coexisting risk factors such as delayed enteral 
feeding, episodes of sepsis and clinical problems 
necessitating surgical intervention.
With regard to the toxicity of parenteral nutri-
tion components, many studies have shown that 
lipids are implicated in the pathogenesis of both 
hepatic steatosis and PNAC, although there was no 
difference in the duration of lipid infusion between 
the PNAC and non-PNAC groups in this study.16 The 
other component of parenteral nutrition, amino 
acids, was also thought to be a possible factor 
responsible for inducing liver dysfunction. Because 
the metabolism of some amino acids is impaired in 
premature infants, pediatric formulations have 
been introduced for sick neonates.
Sepsis is a common complication during 
parenteral nutrition infusion. It may cause cholesta-
sis, as demonstrated in many studies.17,18 The mech-
anism may be due to direct hepatotoxicity caused 
by endotoxin as a result of bacterial overgrowth in 
the intestine. Sepsis episodes were also implicated 
in enteral feeding, and prolonged the duration of 
parenteral nutrition.
Robinson et al demonstrated that SGA was an 
independent risk factor for PNAC,19 but our study 
showed no significant difference between the SGA 
and non-SGA infants. Other potential risk factors 
such as low Apgar scores at 5 minutes of age, the 
number of operations, BPD, PDA and NEC, were not 
significant after adjustment for gestational age and 
birth body weight in this study. These results are 
consistent with those of other studies.4,20
The cut-off points for the five predictors shown 
in Table 3 might be useful tools to clinically predict 
the development of cholestasis. Of these predictors, 
the duration of parenteral nutrition was the most 
significant risk factor for PNAC. However, the du-
ration of parenteral nutrition may not be a good 
predictor because of the time required (> 61 days) 
to meet the cut-off value. Average energy intake 
during the 2nd and 3rd weeks of life might offer an 
alternative predictor for clinical use.
This study has limitations because of its retro-
spective study design and small number of cases. 
Although we could predict PNAC before it devel-
oped, a strategy for the prevention of PNAC has not 
yet been established. Ursodeoxycholic acid is cur-
rently the most widely used agent to treat 
PNAC.21,22 It is also used in patients with cholesta-
sis in our hospital. However, a recent study showed 
that it could not prevent the development of PNAC 
and was ineffective in reducing cholestasis once 
it occurred.23 Parenteral administration of fish oil 
reversed PNAC in some cases,24 but more ran-
domized controlled trial studies are needed to val-
idate this approach. Meanwhile, recently developed 
drugs such as cholecystokinin-octapeptide25 are 
not yet available in Taiwan.
5.  Conclusions
Premature and low birth body weight infants are at 
high risk for PNAC. After adjusting for gestational 
age and birth body weight, prolonged duration of 
parenteral nutrition and episodes of sepsis were 
still strongly associated with the development of 
cholestasis. Low average energy intake during the 
2nd and 3rd weeks of life offers an additional pre-
dictor for the development of PNAC.
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